Back to mobile site

Canaccord Genuity Reiterates a 'Buy' on OraSure Technologies (OSUR); Attention Shifts to HCV Waiver

May 5, 2011 12:11 PM EDT
Get Alerts OSUR Hot Sheet
Price: $3.74 --0%

Rating Summary:
    9 Buy, 8 Hold, 0 Sell

Rating Trend: = Flat

Today's Overall Ratings:
    Up: 6 | Down: 5 | New: 13
Join SI Premium – FREE
Canaccord Genuity reiterates a 'Buy' on OraSure Technologies (NASDAQ: OSUR), PT $10.

Canaccord analyst says, "We reiterate our rating on OSUR following its results last evening that were slightly ahead of expectations. While the Q2 guidance provided was basically in line, investor attention will be on CLIA waiver approval for its HCV test expected late Q2...We anticipate Merck (NYSE: MRK) and Vertex (Nasdaq: VTRX) will demonstrate a sense of urgency to identify and treat patients. Several other compounds are approaching later stages of development."

For more ratings news on OraSure Technologies click here and for the rating history of OraSure Technologies click here.

Shares of OraSure Technologies closed at $8.29 yesterday.


Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Analyst Comments